



***bla* TEM, *bla* SHV and *bla* CTX-M-15 Extended Spectrum Beta-lactamase Produced by *Acinetobacter baumannii*, *Enterobacter cloacae* and *Proteus mirabilis* from Pregnant Women in Three Secondary Health Care Facilities in South-south, Nigeria**

Florence Z. Uyanga^{1*}, Emmanuel O. Ekundayo² and Emmanuel O. Nwankwo²

¹Department of Microbiology, Akwa Ibom State University, Mkpata Enin, Akwa Ibom State, Nigeria.
²Department of Microbiology, Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria.

Authors' contributions

This work was carried out in collaboration among all authors. Author FZU designed the study and wrote the protocol. Author EOE wrote the first draft of the manuscript and proof reading. Authors EOE and FZU managed the analyses of the study and performed the statistical analysis. Author EON managed the literature searches. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JAMB/2019/v18i130154

Editor(s):

(1) Dr. Ana Cláudia Correia Coelho, Department of Veterinary Sciences, University of Trás-os-Montes and Alto Douro, Portugal.

Reviewers:

(1) Nain Taara Bukhari, Aga Khan University Hospital, Pakistan.
(2) Kaunara A. Azizi, Tanzania Food and Nutrition Centre (TFNC), Tanzania.
(3) Pinar Sanlibaba, Ankara University, Turkey.
Complete Peer review History: <http://www.sdiarticle3.com/review-history/50816>

Original Research Article

Received 03 June 2019
Accepted 16 August 2019
Published 23 August 2019

ABSTRACT

Background/Purpose: Based on fact there is high urinary tract infection and increasing treatment failure among pregnant women and this has led to increased mortality and morbidity among pregnant women, and increased stay in the hospital. This study was conducted to evaluate the prevalence of antimicrobial resistance and distribution of *bla*TEM, *bla*CTX-M-15 and *bla*SHV genes among *A. baumannii*, *P. mirabilis* and *E. cloacae* strains isolated from urine samples from pregnant women attending antenatal at three secondary health care facilities south-south Nigeria.

*Corresponding author: E-mail: florenceorok@gmail.com;

Methods: *A. baumannii*, *P. mirabilis* and *E. clocae* strains were isolated and identified using Microbact 24E. The disc diffusion and combined discs methods were used for testing antimicrobial susceptibility. The presence of ESBL was detected using Double Disk Synergy Test (DDST) and CHROMagar respectively. Plasmid extraction was carried out following the protocol of ZR Plasmid Miniprep-Classic extraction kit. Finally, the frequency of resistant genes including *bla*TEM, *bla*CTX-M-15 and *bla*SHV in selected 50 ESBL producing isolates was studied by PCR and using designed primers.

Results: A total of 252 clinical isolates was collected from three secondary health care facilities in south-south, Nigeria. ESBLs were found in 231 (92%) isolates. *bla*CTX-M-15 was the commonest genotype (58.3%), followed by *bla*SHV (43.3%) and *bla*TEM (43.3%).

Conclusion: ESBL positive strains of *Enterobacter clocae*, *Acinetobacter baumannii* and *Proteus mirabilis* are increasingly found in isolates from pregnant women. The widespread use of antibiotics has caused shifts in bacterial development to overcome the existing mechanisms of combating bacterial infections. These strains become resistant to frequently used antibiotics and they can pass the gene to other bacterial strains, the quick detection of these strains in clinical laboratories an essential step. The frequency of genes encoded ESBL isolates of *Enterobacter clocae*, *Acinetobacter baumannii* and *Proteus mirabilis* may be due to abuse and misuse of antibiotics.

Keywords: ESBL blagene; PCR; UTI.

1. INTRODUCTION

Currently, the challenge of gradually increasing resistance to antibiotics has affected the entire world. The hydrolysis and inactivation of beta-lactam antibiotics, through the production of beta-lactamase has been one of the most main resistance mechanisms of many bacterial species, especially in the family Enterobacteriace [1]. Gram-negative pathogens is increasingly associated with ESBLs, hence resulting in the resistance to beta-lactam antibiotics [2].

ESBL positive enterobacterial species are widely disseminating throughout the world [3]. The main reason for development of resistance is mainly the selection and preferential growth of resistant bacteria, together with inhibition of susceptible strains from prolonged use of antibiotic. Extended-spectrum -lactamases (ESBLs) were first described in the 1980s and they have been detected in Gram-negative bacilli [4,5,6].

A typical mechanism of AMR is the production of extended-spectrum beta-lactamase. (ESBL) enzymes, which confer resistance to penicillins, cephalosporins, and monobactams, but not to cephamycins and carbapenems [7,8].

Presently there is an increase in the emergence of ESBL producing bacteria. The increasing resistant to beta-lactam antibiotics used in treating urinary tract infections (UTIs) has made the treatment very challenging and frequently resistant to many of the antimicrobial agents recommended for the treatment of such

infections [9]. Most ESBLs belong to the CTX-M, SHV (Sulphydryl variable) and TEM (Temoniera) families. Due to the production of multiple enzymes such as the inhibitor-resistant ESBL variants and plasmid-borne AmpC, ESBL phenotypes have become more complex [10]. Commercial available chromogenic media such as CHROMagar (Paris, France) have been used to detect ESBL production. Chromogenic culture media is a rapid culture based methods used for detection of ESBL and presumptive organism identification. The media has a chromogenic enzyme substrate as a detection system. Chromogenic substrates consist of chromophor which is linked to an enzyme-recognizing part such as carbohydrate, amino acids or phosphate. Specific enzymes produced by the target micro-organism will cleave to the chromogenic substrate liberating the chromophor which highlight the micro organism by coloration of the grown colony [11]. The aim of this study was to isolate and identify the types of extended spectrum beta-lactamases genes (ESBL) produced by *A.baumannii* and *Enterobacter clocae* and *Proteus mirabilis*.

2. MATERIALS AND METHODS

2.1 Sample Collection

The study was cried out within a period of six months. A total of 660 urine samples were collected from pregnant women attending antenatal at the three secondary health care facilities between July to December, 2018. All pregnant women who were not on any antibiotics

and willing to participate were included in the studies, while those on any antibiotic therapy were excluded from the studies.

Mid stream clean- catch urine samples were collected and inoculated on MacConkey and CHROMagar ESBL and incubated at 37°C for 24 hours. They were examined for growth and colony counts yielding bacterial growth of 10^5 /ml of urine were taken to be significant. Samples were Gram stained and also subjected to Microbact 24E identification.

2.2 Antimicrobial Susceptibility Testing

Antibiotic susceptibility was determined by the disk diffusion method on Mueller-Hinton agar (Oxoid, UK) according to Clinical and Laboratory Standard Institute (CLSI) guidelines. ESBL-producing isolates were screened using double-disk synergy test in accordance with CLSI guidelines [12]. According to CLSI guidelines isolates showing inhibition zone size of ≤ 22 mm with Ceftazidime (30 μ g), ≤ 25 mm with Cefotaxime (30 μ g), ≤ 7 mm with Azetronam (30 μ g) and ≤ 22 mm with Cefodoxime (10 μ g) was identified as potential ESBL producers and shortlisted for confirmation of ESBL production (CLSI, 2010). *E. coli* ATCC 25922 and *S. aureus* 6571 were used as quality control strains.

2.3 Double Disk Synergy Test

Double disk synergy test as described by Jarlier et al. [13] was used to confirm ESBL production. Test isolate was swabbed on the surface of Mueller Hinton agar, then placement of a ceftazidime disk close (20 or 30 mm) to an amoxicillin-clavulanate disk on a plate inoculated with the test organism. A clear extension the zone of inhibition around the disk towards the amoxicillin-clavulanate disk that is centrally placed indicates the production of ESBL. This extension occurred due to the fact that the clavulanic acid present in the augmentin

disc inactivated the ESBL produced by the organism.

Inoculation was also done on CHROMagar ESBL, a completely new and innovative chromogenic medium designed specifically for the Screening of Extended Spectrum β -Lactamase-producing Enterobacteria (ESBL) [14]. Incubation was done for 18-24 hrs. *Escherichia coli* produced pink to burgundy colouration of β -glucuronidase-producing colonies *Klebsiella*, *Enterobacter*, *Serratia*, *Citrobacter* (KESC): green/blue to brownish-green colouration of β -glucosidase-producing colonies. *Proteaeae* (*Proteus*, *Providencia*, *Moraganelia*) produced dark to light brown colouration.

2.4 Statistical Analysis

The SPSS statistical package version (20.0) was used for statistical analysis. A p-value <0.05 was considered as statistically significant.

2.5 Plasmid DNA Analysis

Plasmid extraction was carried out using ZR Plasmid Miniprep-Classic extraction kit according to the manufacturers instruction.

2.6 Detection of ESBL Genes Types by PCR

ESBL producing isolates were amplified using bla TEM/SHVCTX-15, specific primers listed in Table 1. The reaction was performed in Gene Amp PCR system 9700 thermocycler (Thermo Electron Corporation, USA) under the following conditions: Initial denaturation at 94°C for 5 minutes followed by 35 cycles of 30 seconds denaturation at 94°C, 30 seconds annealing at 58°C, 60 seconds extension at 72°C and a final extension at 72°C for 7 minutes. Polymerase chain reaction (PCR) products was separated by electrophoresis in 1.5% agarose gels and stained with ethidium bromide .A molecular marker (DNA laddah size range: 10 kb) was used to assess PCR product size.

Table 1. Primer sequences used to amplify and β -lactamase genes by the PCR technique

Gene	Target	Primer	Product size (bp)	Reference
<i>bla</i> _{TEM}	β -lactam	F: ATAAAATTCTTGAAGACGAAA R: GACAGTTACCAATGCTTAATC	1080	Sharma et al. 2010
<i>bla</i> _{SHV}	β -lactam	F:CACTCAAGGATGTATTGTG R: TTAGCGTTGCCAGTGCTCG	928	Sharma et al. 2010
<i>bla</i> _{CTX-M-15}	β -lactam	F:CGCTTTGCGATGTGCAG R: ACCGCGATATCGTTGGT	550	Sharma et al. 2010

3. RESULTS AND DISCUSSION

During a six-month period, a total of 252 uropathogens from pregnant women attending antenatal at Government general hospital, Eket, Ikot Ekpene and Oron were identified. 231 isolates were confirmed as potentially ESBL producers using DDST and CHROMagar ESBL. Occurrence of ESBL isolates was as follows: *Enterobacter cloacae* (57%), *A. baumannii* (13.5%), *Proteus mirabilis* (32%), (Table 2).

Fifty ESBL producing isolates were selected for plasmid DNA extraction and *bla* gene amplification: *P. mirabilis* n=12, *A. baumannii* n=20, *Enterobacter cloacae* n=18. Plasmid DNA of size 10kb was extracted from the 50 isolates (Fig. 4). CTX-M-15 type ESBL gene was found in 17% of *P.mirabilis*, 25% of *A. baumannii* and 17% of *E. cloacae*, (Fig. 3) *bla* TEM ESBL resistant gene was found in 8.3% of *P. mirabilis*, 35% of *A. baumannii*, none was found in *E. cloacae* (Fig. 1) *bla* SHV resistant gene was found in 35% of *A. baumannii*, none was found in *E. cloacae* (Fig. 3). In this study, antimicrobial susceptibility testing of *A. baumannii*, *E. cloacae*, and *P. mirabilis* isolates originally showed highly significant resistance to different types of antibiotics. This resistance can be due to the presence of specific genes of ESBL such as *bla*TEM, *bla*CTX-M-15 and *bla*SHV. Knowing the types and frequency of these genes helps us to make a good decision for the treatment process of patients effectively.

High level of multi-drug resistance including Cefotaxime (CTX), Cefazidime (CAZ), Amoxicillin/clavulanic acid (AMC), Ofloxacin (OFX) and Amikacin (Ak) was observed among the isolates under the study. Various factors, such as the abuse of antibiotics, the spread of clonal resistant microorganisms, can cause the release of highly resistant pathogens. Previous studies showed that the prevalence of *A. baumannii* MDR isolates ranged from 32.7% to 100% [15,16,17,18,19]. Previous researches has reported that the prevalence of ESBL producing *E. cloacae* isolates ranged from 18% to 75% [20,21] while our studies reports a prevalence of 57%. In the present study 32% of *P. mirabilis* was ESBL producer was consistent with previous studies by Habibu and Orhue [22,23].

Among the mechanisms that create resistance to drugs, ESBLs play an important role in resistance to commonly used antibiotics such as penicillin and cephalosporins. ESBL genes, due to the widespread diffusion of pathogens in the community through plasmids and integrons, can further lead to an increase in resistance to drugs including MDR isolates [24].

Safari et al. [24] reported that *SHV* (58%) and *TEM* (20%) were the highest numbers of ESBL genes in their study [14]. Azhar et al. [25] based on a study that conducted in Iraq, reported that *SHV* (25%) was the most frequently detected ESBL gene [26]. Reza et al. [27] reported that






Fig. 1. PCR product of *bla* TEM (Line 1 10kb DNA ladder,5, 7 lower gel)



2

Fig. 2. PCR product of *bla*_{SHV} (Line 1:10kb DNA ladder, 4, 5, 6 lower gel)



3

Fig. 3. PCR product of *bla*_{CTX-M-15} (Line 1:10kb DNA ladder, 2,5, and 6 upper gel, Line 1:10kb DNA ladder, 3,4 lower gel)

TEM (52.1) was the most frequently detected ESBL gene. Khalilzadegan and colleagues [18] identified that *CTX-M* and *TEM* have most ESBL genes [28] while in our studies *bla*_{CTX-M-15} (58.3) was the most frequently detected gene.

The reason to the observed differences in resistance patterns and the prevalence of

A. baumannii, *E. clocae* and *P. mirabilis* in various investigations include the following; abuse and misuse of antibiotics, differences in the type of antibiotics used, long-term hospitalization, type of samples taken, differences in diagnostic methods used to identify genes, geographical conditions, gender and etc [29,30].




Fig. 4. Agarose gel Electrophoresis of plasmids recovered from ESBL producing bacterial isolates. Lane M: 10kb DNA ladder, lanes 1=*P. mirabilis*, Lanes 5, 6-*A. baumannii* (Upper gel) Lanes 4,5,6 =*E. cloacae*

Table 2. Frequency of ESBL producing isolates across the three study area

Bacterial isolates	Total	%
<i>Acinetobacter baumannii</i>	31	13.5
<i>Acinetobacter haemolyticus</i>	7	3
<i>A. iwoffii</i>	3	1.3
<i>E. coli</i>	10	4.3
<i>Citrobacter youngae</i>	1	0.4
<i>Citrobacter freundii</i>	1	0.4
<i>Citrobacter diversus</i>	1	0.4
<i>Hafnia alvei</i>	17	7.4
<i>Staphylococcus aureus</i>	17	7.4
<i>Enterobacter cloacae</i>	57	24.8
<i>S. maltophilia</i>	12	5.2
<i>Proteus mirabilis</i>	32	13.9
<i>Salmonella subspecies</i>	7	3
<i>P. stuarti</i>	1	0.4
<i>Klebsiella pneumoniae</i>	2	0.7
<i>Enterobacter hormaechei</i>	4	1.7
<i>Enterobacter gresoviae</i>	1	0.4
<i>Serratia marcescens</i>	7	3
<i>Serratia luquefaciens</i>	1	0.4
<i>Morganella morganii</i>	6	2.6
<i>Citrobacter sakazaki</i>	2	0.4
Total	231	100

Table 3. Detection of *bla*_{ESBL} genes of SHV, TEM and CTX-M-15 in ESBL producing *Proteus mirabilis*, *Acinetobacter baumannii* and *Enterobacter cloacae*

Strain identification	No. of isolates tested	<i>bla</i> _{SHV}	<i>bla</i> _{TEM}	<i>bla</i> _{CTX-M-15}
<i>Proteus mirabilis</i>	12	1(8.3)	1(8.3)	2(16.7)
<i>Acinetobacter baumannii</i>	20	7(35)	7(35)	5(25)
<i>Enterobacter cloacae</i>	18	0	0	3(16.6)
Total	50	8(16)	8(16)	10(20)

No. (%) positive isolates

4. CONCLUSION

In the present study *bla*_{CTX-M-15} had the highest frequency of 58.3% obtained from pregnant women attending antenatal at the three study areas. The biological characteristics of ESBL isolates suggest that the predominant *bla*_{CTX-M-15} is carried by plasmids. Antibiotic use, poverty, hygiene failures has enhance the high increment in ESBL producing Gram negative organism disseminating in African continent [31].

ETHICAL APPROVAL

Ethics committee of Akwa Ibom State Ministry of health, provided ethical clearance for the study. Participants' privacy and confidentiality have been assured (no names have been used, only serial numbers were used) and all data and results have been handled and treated confidentially. Ref:MH/PRS/99/VOL.IV/200.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

- Akcam FZ, Gönen I, Kaya O, Yaylı G. The determination of susceptibility of beta-lactam antibiotics and extended spectrum betalactamase production in Enterobacteriaceae which responsible from nosocomial infections. Med. J. Sdu. 2004;11:6-9.
- Kimura S, Ishii Y, Tateda K, Yamaguchi K. Predictive analysis of ceftazidime hydrolysis in CTX-M-type -lactamase family members with a mutational substitution at position 167. Int. J. Antimicrob. Agents. 2007;29:326-331.
- Timko J. Changes of antimicrobial resistance and extended spectrum beta-lactamase production in *Klebsiella* spp. strains. J. Infect. Chemother. 2004;10:212-215.
- Kiratisin P, Apisarnthanarak A, Laesripa C, Saifon P. Molecular characterization and epidemiology of extended-spectrum -lactamase-producing *Escherichia coli* and *Klebsiella pneumonia* isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic. Antimicrob. Agents Chemother. 2008;52:2818-2824.
- Cheng J, Ye Y, Wang YY, Hui L, Xu L, Jiabin L. Phenotypic and molecular characterization of 5 novel CTX-M enzymes carried by *Klebsiella pneumoniae* and *Escherichia coli*. Acta Pharmacol. Sin. 2008;29:217-225.
- Morris D, O'Hare C, Glennon M, Maher M, Corbett-Feeney G, Cormican M. Extended-spectrum -lactamases in Ireland, including a novel enzyme, TEM-102. Antimicrob. Agents Chemother. 2003;47:2572-2578.
- Paterson David L, Bonomo Robert A. Extended-spectrum beta-lactamases: A clinical update. Clin Microbiol Rev. 2005;18(4):657-86.
- Pitout Johann DD, Nordmann Patrice, Laupland Kevin B, Poirel Laurent. Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother. 2005;56(1):52-9.
- Ben-Ami R, Rodríguez-Baño R, Arslan HJ, et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in non-hospitalized patients. Clin Infect Dis. 2009;49:682.
- Mohanty S, Gaiind R, Ranjan R, Deb M. Use of cefepime-clavulanate ESBL Etest for detection of extended spectrum beta-lactamase in AmpC co-producing bacteria. J Infect Dev Ctries. 2009;4:24-29.
- Gazin M, Paasch F, Goostens H, Malhotra-Kumar S. Current trends in culture based and molecular detection of extended

- spectrum β -lactamase harbouring and Carbapenem – resistant Enterobacteriaceae. J Clin Microbiol. 2012;50(4):1140-1146.
12. Clinical and Laboratory Standard Institute. Performance standard for antimicrobial susceptibility testing 22nd informational supplement, M100-S20. Wayne, P A: Clinical and Laboratory Standard Institute; 2012.
 13. Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended broad-spectrum β -lactamases conferring transferable resistance to newer β -lactam agents in Enterobacteriaceae: Hospital prevalence and susceptibility patterns. Rev. Infect. Dis. 1988;10:867–878.
 14. Safari M, Mozaffari N, Bahador AS, Jafar A, Alikhani MY. Prevalence of ESBL and MBL encoding genes in *Acinetobacter baumannii* strains isolated from patients of intensive care units (ICU). Saudi J Biol Sci. 2015;22(4):424-9.
 15. Agodi A, Barchitta M, Quattrocchi A, et al. Antibiotic trends of *Klebsiella pneumoniae* and *Acinetobacter baumannii* resistance indicators in an intensive care unit of Southern Italy, 2008-2013. Antimicrob Resist Infect Control. 2015;4:43.
 16. Mirnejad R, Vafaei S. Antibiotic resistance patterns and the prevalence of ESBLs among strains of *A. baumannii* isolated from clinical specimens. J Gen Microbes Immunity. 2013;1-8.
 17. Kheltabadi RF, Moniri R, Shajari GR, Nazem Shirazi MH, Musavi SGA, Ghasemi A, et al. Antimicrobial susceptibility patterns and the distribution of resistance genes among acinetobacter species isolated from patients in Shahid Beheshti Hospital, Kashan. Feyz J Kashan Univ Med Sci. 2009;12(4).
 18. Khalilzadegan S, Sade M, Godarzi H, et al. Beta-lactamase encoded genes *bla*TEM and *bla*CTX among *Acinetobacter baumannii* species isolated from medical devices of intensive care units in Tehran hospitals. Jundishapur J Microbiol. 2016;9(5):e14990.
 19. Shakibaie MR, Adeli S, Salehi MH. Antibiotic resistance patterns and extended-spectrum β -lactamase production among *Acinetobacter* spp. isolated from an intensive care unit of a hospital in Kerman, Iran. Antimicrob Resist Infect Control. 2012;1(1):1.
 20. Majid Akbari, Bita Bakhshi, Shahin Najar Peerayeh. Particular distribution of enterobacter cloacae strains isolated from urinary tract infection within clonal complexes. Iranian Biomedical Journal. 2016;20(1):49-55.
 21. Kobra Salimian Rizi, Shahin Najar Peerayeh, Bita Bakhshi, Mohammad Rahbar. Emergence of *bla*CTX-M-15 gene and its transferability in *Enterobacter* spp. isolated from the hospitals of Tehran, Iran. Avicenna J Clin Microb Infec. 2015;2(3):e29691.
 22. Habibu AU. Prevalence of *Proteus mirabilis* and *Pseudomonas aeruginosa* among female patients with suspected urinary tract infections attending Muhammad Abdullahi Wase specialist hospital, Kano, Nigeria. The International Journal of Engineering and Science (IJES). 2014;2319–1813. ISSN (p): 2319 – 1805.
 23. Orhue OP. Antibioqram study of *Proteus* spp. bacterial isolates from uropathogenic infections in University of Benin Teaching Hospital, Nigeria. Current Research in Bacteriology. 2014;7(1):12-21.
 24. Safari MM, Nejad AS, Bahador A, Jafari R, Alikhani MY. Prevalence of ESBL and MBL encoding genes in *Acinetobacter baumannii* strains isolated from patients of intensive care units (ICU). Saudi J Biol Sci. 2015;22(4):424-9.
 25. Azhar, et al. Molecular detection of extended-spectrum betalactamases in clinical isolates of *A. baumannii*. J Biol Agric Health. 2013;3(7):32-9.
 26. Sedighi I, Arabestani MR, Rahimbakhsh A, Karimitabar Z, Alikhani MY. Dissemination of extended-spectrum β -lactamases and quinolone resistance genes among clinical isolates of uropathogenic *Escherichia coli* in children. Jundishapur J Microbiol. 2015;8(7):e19184.
 27. Reza B, Mohammad E, et al. Prevalence of extended spectrum beta-lactamase producing *Klebsiella pneumoniae*: First systematic review and meta-analysis from Iran. Journal of Global Antimicrobial Resistance. 2019;18:12-21.
 28. Khalilzadegan S, Sade M, Godarzi H, et al. Beta-lactamase Encoded genes *bla*TEM and *bla*CTX among *Acinetobacter baumannii* species isolated from medical devices of intensive care units in Tehran hospitals. Jundishapur J Microbiol. 2016;9(5):e14990.

29. Darvishi M. Virulence factors profile and antimicrobial resistance of *A. baumannii* strains isolated from various infections recovered from immunosuppressive patients. 2016;9(3):1057-62.
30. Woerther PL, Burdet C, Chachaty E, Andremont A. Trends in human fecal carriage of extended-spectrum beta-lactamase in the community. Towards the globalization of CTX-M-15. Clin Microbial Rev. 2013;26:744-58.
31. Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: Hospitals prevalence and susceptibility patterns. Rev Infect Dis. 1988;10(4):867-78.

© 2019 Uyanga et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
<http://www.sdiarticle3.com/review-history/50816>